Abstract: Provided are a means for the prevention and treatment of obesity and/or insulin resistance and, particularly, pharmaceutical drugs for the treatment of obesity and/or insulin resistance under the influence of Follistatin-like 3 (FSTL3). Specifically, provided is an insulin resistance improving drug comprising an FSTL3 inhibitor as an active ingredient, particularly, the insulin resistance improving drug, wherein the FSTL3 inhibitor is one of (A) a substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3, (B) an inhibitor for expression of FSTL3, and (C) a competitor of FSTL3.

Abstract: Provided are a means for the prevention and treatment of obesity and/or insulin resistance and, particularly, pharmaceutical drugs for the treatment of obesity and/or insulin resistance under the influence of FSTL3. Specifically, provided is an insulin resistance improving drug comprising an FSTL3 inhibitor as an active ingredient, particularly, the insulin resistance improving drug, wherein the FSTL3 inhibitor is one of (A) a substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3, (B) an inhibitor for expression of FSTL3, and (C) a competitor of FSTL3.

Abstract: Provided is a new anti-inflammatory drug that produces an anti-inflammatory effect by modulating macrophage function. Specifically, a new anti-inflammatory drug that produces an anti-inflammatory effect through induction of M2 macrophages using activin species is provided.

Abstract: Provided is a method of measuring the expression level of FSTL3 gene in a biological sample and correlating the measured expression level with the detection of a risk of developing diabetes. Also provided is a method of measuring the expression level of FSTL3 gene in an individual with a BMI value less than 25 not clinically determined as obesity and correlating the measured expression level with the detection of a risk of developing obesity. Further provided is a method of measuring the expression level of FSTL3 gene in an individual with a BMI value less than 25 and correlating the measured expression level with the detection of a risk of developing diabetes. Further provided is a method of measuring an inhibin ?B gene expression level and correlating the ratio of expression level of FSTL3 gene to inhibin ?B gene with the detection of a risk of developing obesity or diabetes.